At the beginning of the COVID-19 pandemic, Rady Johnson and Beth Holly knew their companies needed to be transparent when creating and rolling out treatments for the never-before-seen virus.

From the outset of the pandemic, Johnson, the chief compliance, quality and risk officer at Pfizer in New York, and Holly, the chief compliance officer at Regeneron Pharmaceuticals Inc. in Tarrytown, New York, acknowledged public skepticism of the pharmaceutical industry.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]